Stay informed on developments in cancer and oncology diagnosis, prevention and treatment through these curated webinars. As the race toward a cure for cancer continues, advances in cancer research are constantly revealed as innovation in the field of oncology progresses.
The Keynote Address will highlight eight actions that individuals can take to reduce their cancer risk. These recommendations span lifestyle modifications, cancer screening and molecular prev...
Variation in gene expression among cell types, tissues, and organisms is commonly examined by reverse transcription quantitative PCR, or RT-qPCR. In this process, RNA is isolated from sample...
Artificial Intelligence (AI) is a computer program designed to perform operations typical of human intelligence, such as self-learning. AI is taking over different fields in science; we alre...
Single-cell RNA sequencing (scRNA-seq) is an important technology that reveals gene expression differences between different cell types. Yet scRNA-seq data can be challenging to analyze and...
Molecular diagnostic tests are currently used for infectious disease testing due to the superior sensitivity and specificity that can be obtained. Due to the success that has been obtained w...
Tumors invade surrounding tissue as cancer progresses, but the heterogeneity of cell types at the tumor-stroma interface and the complexity of their interactions has hampered mechanistic ins...
Informed consent (IC) is a fundamental aspect of ethical clinical research, safeguarding the rights and well-being of participants. It empowers participants with comprehensive information ab...
Soluble cytokine biomarkers are the master regulators of cell-to-cell communication-- the means by which one cell tells another what to do or where to go. Determining the biomarker signature...
The next leap in oncology therapeutics demands speed, precision, and rapid molecular innovation — and AI-driven antibody design (AIDD) is beginning to deliver. In this talk, we will un...
Natural killer (NK) cells, immune cells with an innate ability to recognize and eliminate cancer cells, have emerged as attractive effectors in immunotherapy, owing in large part to their ab...
Cancer is a multifactorial disease, and its genesis and progression are extremely complex. The scope of precision oncology is rapidly expanding to address previously undruggable targets. The...
There are known health outcome disparities among those with pancreatic neuroendocrine tumors (pNET) of minority race and those living with adverse social determinants of health (SDOH) (rural...
Copy-number alterations and chromosomal translocations are widespread in cancer and frequently causing oncogenic mutations that drive tumorigenesis and therapy resistance. Despite their preva...
The recent outbreak of the Coronavirus Disease 2019 (COVID-19) has spread all over the world and raised global concerns. Rapid and early detection of the novel coronavirus SARS-CoV-2, the ca...
Acute lymphoblastic leukemia is the most common cancer in children and adolescents. While current treatments have resulted in 85-90% cure, the remaining 10-15% cases represent the leading cau...
Summary: Cancer neoantigens are highly specific to the tumor, potently immunogenic and can be targeted by both vaccines and engineered cellular therapies. This talk will introduce the defini...
We started our experience with prostate cancer in 2002 with primitive robotic platforms. Our main goal was to provide an alternative to open and laparoscopic surgery....
Immunotherapy has changed the landscape of oncology, improving survival rates for many patients across a variety of malignancies. Two antibody-based immunotherapies, immune checkpoint inhibi...
Over the past 10 years, we have come to a greater understanding of the pathogenesis of men who succumb to prostate cancer. One critical aspect is the role of molecular drivers in patients wi...
The lack of diverse participation in clinical research and trials has been a long-standing national problem that has been brought to the forefront due to COVID 19. In cancer research less th...
Neoantigens are peptides derived from patient-specific and tumor-specific mutations, which can be recognized by the immune system and mediate tumor recognition that leads to immune destructi...
We recently determined that concurrent inhibition of autophagy, using the lysosomal inhibitor chloroquine (CQ), and of ERK, using a small molecule ERK inhibitor (ERKi), synergistically suppr...
Background: Healthcare access (HCA) encompasses five important dimensions: Affordability, Availability, Accessibility, Accommodation and Acceptability. Published studies of cancer typically...
In this webinar, we will cover time-saving tips to help increase your PCR productivity. We will address common PCR pitfalls that can be avoided with innovations in enzymes, instruments, and...
Mathematical methods can be used to study evolutionary processes associated with carcinogenesis. Selection, mutation, and drift all play a role in cancer dynamics and cancer treatment. I wil...
Data suggests that genetics comprises 42-58% of the prostate cancer risk. GWAS has found about 43% of the risk SNPs in Blacks and European Americans. Most of the SNPs that have been discover...
The Keynote Address will highlight eight actions that individuals can take to reduce their cancer risk. These recommendations span lifestyle modifications, cancer screening and molecular prev...
